JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Autoimmune Diseases
Interventions
GENETIC

JY231

Infusion of JY231 Injection by dose of 1-10×10\^6 TU/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)

Trial Locations (1)

030000

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors
lead

Shanxi Bethune Hospital

OTHER

NCT06243159 - JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases | Biotech Hunter | Biotech Hunter